“Insulin lispro (Humalog) 7 units subcutaneous TID, 15 minutes before meal”.
The information behind Insulin lispro is that it was approved by the U.S. Food and Drug Administration (FDA) in 1996, becoming the first new insulin product to appear in the U.S. market in 14 years (Lilley, L. L., Savoca, D., & Lilley, L. L. 2011). It can be administered through a subcutaneous route, it has a 15 minutes onset. Its peak plasma concentration is 1 to 2 hours and its elimination half-life is usually 80 minutes, with 3 to 5 hours duration of action.…